

Marc Bonneville – bio sketch

Marc Bonneville, (48), D.V.M. and CNRS research director, is the head of an INSERM research center dedicated to cancer research, which involves about 200 people in Nantes (France). He started to work in 1983 on transplantation immunology and then switched from 1987 to 1989 to more upstream immunological issues dealing with mouse cellular immune responses during his postdoctoral training in S. Tonegawa's laboratory (MIT, Boston). Since 1990 he has been heading a research group working on human cellular immune responses in various physiopathological contexts, with a main focus on so-called « transitional immunity » mediated by $\gamma\delta$ and NKT cells on the one hand, and virus-specific conventional T cell responses on the other hand. Together with 5 other scientists, he founded in 1999 a biotech company (Innate Pharma SA) that has been developing new immunotherapeutic approaches targeting innate lymphocytes ($\gamma\delta$ T and NK cells) in the field of infectiology and oncology. Marc Bonneville is author of more than 170 scientific papers and 7 patents. He has received several awards and prizes (Bronze and Silver CNRS medal, Halpern and LNCC prizes, ...). He has been involved in more than 20 scientific councils and committees and has been an advisor of the INSERM General Director in the field of immunology and biotherapies from 2000 until 2007.